Participants essentially held on to their prior weight loss, with a negligible difference of +0.9 kg.
A +5.0 kg gain on a baseline of 90.9 kg implies roughly a +5.5% weight increase over one year after switching to orforglipron.
Safety was "consistent with Phase 3" (meaning GI adverse events persisted). Implication: Zepbound switchers regained weight while still dealing with side effects, raising skepticism about the net benefit for this group.